New Developments in Lung Cancer Treatment


January 30th, 2015 - January 30th, 2018
1.00 AMA PRA Category 1 Credit Hours

Description

Today on MedNet21, we're going to discuss New Developments in Lung Cancer Treatment.
The webcast is no longer available.
Post-Test taking for this webcast is no longer available.

Dates and Times

End Date: 1/30/2018

Objectives

As a result of this educational activity, webcast participants will be able to: GAIN an understanding of the importance of genomic testing in the initial workup of patients with lung cancer. EXPLAIN the evolving role of immune mediated therapy in lung cancer; RECOGNIZE the clinical benefit for patients receiving targeted therapies; and DESCRIBE the patient characteristics commonly associated with actionable mutations in lung cancer.

Webcasts Files

File Link

New Developments in Lung Cancer Treatment - 2

Download

New Developments in Lung Cancer Treatment - 4

Download

Disclosure Information for Planning Committee Members and Speakers

Download

Speakers

  • Dr. James Allen, MD
    • New Developments in Lung Cancer Treatment
  • Dr. Erin Bertino, MD
    • New Developments in Lung Cancer Treatment
  • Dr. Gregory Otterson, MD
    • New Developments in Lung Cancer Treatment

Accreditation

The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians

The Center for Continuing Medical Education (CCME) at The Ohio State University designates this webcasts for a maximum of 1.00 AMA PRA Category 1 Credit(s) . Physicians should only claim credit commensurate with the extent of their participation in the activity.